Article
Psychiatry
Ivo H. Cerda, Paul J. Fitzgerald
Summary: The article presents a neurochemical model of unipolar major depressive disorder and predicts optimal pharmacological treatment based on different subtypes of depression. It suggests using different medications for high and low NE/5HT depression, and predicts the effects of rapidly acting antidepressants on different subtypes.
PSYCHIATRY RESEARCH
(2021)
Review
Medicine, General & Internal
Morton E. Tavel
Summary: The placebo effect refers to improvements in illnesses or subjective symptom reduction caused by interventions with no known physical effects, while the nocebo effect refers to undesirable symptoms or illnesses following interventions with no known physical effects, and it may play a role in chronic illnesses without objective confirmation. Both placebo and nocebo effects are powerful and must be understood by practitioners and researchers in clinical medicine. Individual caregivers can apply these principles to modify patient care outcomes.
AMERICAN JOURNAL OF MEDICINE
(2022)
Article
Psychology, Clinical
Paul M. Cinciripini, George Kypriotakis, Charles Green, David Lawrence, Robert M. Anthenelli, Jennifer Minnix, Janice A. Blalock, Diane Beneventi, Chad Morris, Maher Karam-Hage
Summary: This study evaluated the safety and efficacy of smoking cessation pharmacotherapy among smokers with major depressive disorder (MDD). The results suggest that varenicline plus counseling may be the best pharmacological option for treating smoking in MDD smokers, including those with recurrent episodes, due to its higher efficacy effect size and similar risk of adverse events.
DEPRESSION AND ANXIETY
(2022)
Article
Medicine, General & Internal
Robin von Rotz, Eva M. Schindowski, Johannes Jungwirth, Anna Schuldt, Nathalie M. Rieser, Katharina Zahoranszky, Erich Seifritz, Albina Nowak, Peter Nowak, Lutz Jaencke, Katrin H. Preller, Franz X. Vollenweider
Summary: In this double-blind, randomized clinical trial, a single, moderate dose of psilocybin was found to significantly reduce depressive symptoms compared to a placebo condition for at least two weeks, with no serious adverse events recorded. Larger, multi-centric trials with longer follow-up periods are needed to further optimize this novel treatment paradigm.
Article
Clinical Neurology
Yitan Yao, Qiongyao Yang, Yue Wang, Chuanchuan Chen, Wenhui Wang, Miaomiao Zhang, Yongjie Zhong, Xiaoping Yuan, Yueyue Zhang, Huanzhong Liu, Kai Zhang
Summary: This study is the first large-scale study to examine the age of onset and risk of relapse at the individual level in a Chinese population. It found that adolescent onset is more susceptible to the chronicity of Major Depressive Disorder (MDD).
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Chemistry, Medicinal
Vahdad Varzaghani, Masoomeh Sharifi, Reza Hajiaghaee, Sara Bagheri, Saeideh Momtaz, Zahra Tarassoli, Ali Razmi
Summary: This study aimed to evaluate the efficacy and safety of propolis as a complementary therapy for depressive disorder. The results showed that propolis could safely attenuate symptoms of moderate-severe depression, possibly due to its rich content of phenolic acids and flavonoids.
PHYTOTHERAPY RESEARCH
(2022)
Article
Clinical Neurology
Saba Hoobehfekr, Hossein Sanjari Moghaddam, Mohammadreza Shalbafan, Maryam Ghazizadeh Hashemi, Mohammad Mehdi Pirmoradi, Amirhossein Sakenian, Amirhossein Poopak, Shayan Kashefinejad, Masoomeh Yarahmadi, Shahin Akhondzadeh
Summary: Combination therapy of tipepidine with citalopram can effectively improve symptoms of patients with major depressive disorder in a shorter period of treatment, with higher rates of remission and response. There was no significant difference between the two groups in baseline parameters or frequency of side-effects. Further studies with larger sample sizes and longer follow-up treatment are needed to confirm these findings.
PSYCHIATRY AND CLINICAL NEUROSCIENCES
(2021)
Article
Clinical Neurology
Shuntaro Natsume, Hajime Baba, Hitoshi Maeshima, Takao Saida, Naoto Yoshinari, Kentaro Shimizu, Toshihito Suzuki
Summary: Depression is a risk factor for Alzheimer's disease, and changes in A13 protein metabolism may contribute to the transition from depression to AD. This study found that elderly patients with depression had decreased A1342 levels at admission, but these levels recovered to healthy levels 1 year after remission.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Clinical Neurology
Anna Feeney, Rebecca S. Hock, Maurizio Fava, Jesus M. Hernandez Ortiz, Nadia Iovieno, George Papakostas
Summary: This systematic review and meta-analysis examines industry-funded studies on the efficacy of antidepressants in children and adolescents with Major Depressive Disorder (MDD). The study finds that antidepressants have small effects on MDD in this population, possibly due to study design factors and the application of antidepressants developed for adults. The findings highlight the need for tailored drug development and consideration of placebo response in pediatric MDD trials.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Pharmacology & Pharmacy
Matteo R. Di Nicola, Andrea Pontara, George E. N. Kass, Nynke Kramer, Ignazio Avella, Riccardo Pampena, Santo Raffaele Mercuri, Jean Lou C. M. Dorne, Giovanni Paolino
Summary: Snakebites in Europe are mainly caused by species of the Vipera genus in the Viperidae family. The venom composition is diverse, leading to various symptoms ranging from pain to tissue damage. Prompt immobilization, compression, and appropriate medical treatment are crucial for managing snakebites effectively.
Article
Clinical Neurology
Muriel Vicent-Gil, Sara Gonzalez-Simarro, Beatriz Raventos, Javier Vera, Eduardo D. Marin Martinez, Carlota Sabate-Cao, Josefina Perez-Blanco, Dolors Puigdemont, Javier de Diego-Adelino, Carlo Alemany, Maria Serra-Blasco, Narcis Cardoner, Maria J. Portella
Summary: This study aimed to investigate the impact of INCREM on psychosocial functioning and cognitive performance in clinically remitted depressed patients. The results showed significant improvements in psychosocial functioning and cognitive performance in the INCREM group, which were maintained six months later.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Neurosciences
Aida Khadivi, Parnian Shobeiri, Sara Momtazmaneh, Farhaneh-Sadat Samsami, Mohammadreza Shalbafan, Elham Shirazi, Shahin Akhondzadeh
Summary: This study investigated the safety and efficacy of combining phosphodiesterase-3 inhibitor cilostazol with sertraline in the treatment of major depressive disorder (MDD). The results showed that patients in the cilostazol group had lower depression severity scores, higher remission rate, and faster response time compared to the placebo group. No serious adverse effects were observed.
PSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Alexander Refisch, Zuemruet Duygu Sen, Tilman E. Klassert, Anne Busch, Bianca Besteher, Lena Vera Danyeli, Dario Helbing, Ulrike Schulze-Spaete, Andreas Stallmach, Michael Bauer, Gianni Panagiotou, Ilse D. Jacobsen, Hortense Slevogt, Nils Opel, Martin Walter
Summary: Depression has a high prevalence and is a major cause of disability worldwide. Current treatment options for depression are not optimal, with only around 50% of patients responding well. This is likely due to the diverse clinical presentation of major depression disorder (MDD) and the underlying pathophysiological mechanisms. Emerging evidence suggests that immunometabolic dysregulation and the microbiome play important roles in atypical depressive symptoms. Targeting these biological factors in more homogeneous presentations of MDD may lead to novel therapeutic strategies for treatment-resistant depression.
Article
Clinical Neurology
Christoph Kraus, Alexander Kautzky, Victoria Watzal, Anna Gramser, Bashkim Kadriu, Zhi-De Deng, Lucie Bartova, Rupert Lanzenberger, Daniel Souery, Stuart Montgomery, Julien Mendlewicz, Joseph Zohar, Giuseppe Fanelli, Alessandro Serretti, Siegfried Kasper
Summary: Individuals with major depressive disorder (MDD) are at higher risk for obesity, and weight gain is a predisposing factor for depression. Clinical data suggest that suicide risk is also elevated in obese patients. Monitoring weight gain in individuals with MDD should be a priority in clinical practice.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Psychiatry
Louis Simon, Martin Blay, Filipe Galvao, Jerome Brunelin
Summary: This study aimed to investigate the predictive value of baseline EEG settings on future clinical response to ECT in patients with depressive disorder. Results showed a correlation between P300 amplitude, coherence, and connectivity measures with remission, while sleep EEG recordings did not seem to be correlated with remission after ECT. Further large-scale prospective studies are needed to identify optimal EEG parameters associated with clinical response to ECT in depressive disorder.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Clinical Neurology
Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns
Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2024)